1-2 of 2
Robert Janssen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

Ezra E.W. Cohen, Lisle Nabell, Deborah J. Wong, Terry Day, Gregory A. Daniels, Mohammed Milhem, Sanjeev Deva, Michael Jameson, Orlando Guntinas-Lichius, Mohammed Almubarak, Matthew Strother, Eric Whitman, Michael Chisamore, Cynthia Obiozor, Teresa Bagulho, Jose Gomez-Romo, Cristiana Guiducci, Robert Janssen, Erick Gamelin, Alain P. Algazi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1157–1166.
https://doi.org/10.1158/1078-0432.CCR-21-1411
Published: 15 March 2022
View article titled, Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial
Open the PDF for Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

Edward B. Garon, Alexander I. Spira, Melissa Johnson, Lyudmila Bazhenova, Joseph Leach, Amy L. Cummings, Albert Candia, Robert L. Coffman, Mary J. Janatpour, Robert Janssen, Erick Gamelin, Laura Q.M. Chow
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4566–4573.
https://doi.org/10.1158/1078-0432.CCR-21-0263
Published: 15 August 2021
View article titled, A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer
Open the PDF for A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer in another window
Includes: Supplementary data